Acta Medica Iranica 2017. 55(3):200-208.

Precision Medicine Approach to Anaplastic Thyroid Cancer: Advances in Targeted Drug Therapy Based on Specific Signaling Pathways
Hilda Samimi, Parviz Fallah, Alireza Naderi Sohi, Rezvan Tavakoli, Mahmood Naderi, Masoud Soleimani, Bagher Larijani, Vahid Haghpanah


Personalized medicine is a set of diagnostic, prognostic and therapeutic approaches in which medical interventions are carried out based on individual patient characteristics. As life expectancy increases in developed and developing countries, the incidence of diseases such as cancer goes up among people in the community. Cancer is a disease that the response to treatment varies from one person to another and also it is costly for individuals, families, and society. Among thyroid cancers, anaplastic thyroid carcinoma (ATC) is the most aggressive, lethal and unresponsive form of the disease. Unfortunately, current drugs are not targetable, and therefore they have restricted role in ATC treatment. Consequently, mortality of this cancer, despite advances in the field of diagnosis and treatment, is one of the most important challenges in medicine. Cellular, molecular and genetic evidences play an important role in finding more effective diagnostic and therapeutic approaches. Review of these evidences confirms the application of personalized medicine in cancer treatment including ATC. A growing body of evidence has elucidated that cellular and molecular mechanisms of cancer would pave the way for defining new biomarkers for targeted therapy, taking into account individual differences. It should be noted that this approach requires further progress in the fields of basic sciences, pharmacogenetics and drug design. An overview of the most important aspects in individualized anaplastic thyroid cancer treatment will be discussed in this review.


Precision medicine; Anaplastic thyroid cancer; Signal pathways; Pharmacogenetics; Therapy

Full Text:



Chen R, Snyder M. Systems biology: personalized medicine for the future? Curr Opin Pharmacol


Adams F. The genuine works of Hippocrates. Sydenham society; 1849 [cited 17.[

Wheeler DA, Wang L. From human genome to cancer genome: the first decade. Genome Res 2013;23:1054-62.

Snyder M, Du J, Gerstein M. Personal genome sequencing: current approaches and challenges. Genes Dev 2010;24:423-31.

Snyder M, Weissman S, Gerstein M. Personal phenotypes to go with personal genomes. Mol Sys Biol


Patel JN. Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives. Pharmacogenomics Pers Med 2016;9:65-77.

Rasool M, Malik A, Naseer MI, Manan A, Ansari SA, Begum I, et al. The role of epigenetics in personalized medicine: challenges and opportunities. BMC Med Genomics 2015;8:S5.

Network D, Schreiber SL, Shamji AF, Clemons PA, Hon C, Koehler AN, et al. Towards patient-based cancer therapeutics. Nat Biotechnol 2010;28:904-6.

Moch H, Blank P, Dietel M, Elmberger G, Kerr K, Palacios J, et al. Personalized cancer medicine and the future of pathology. Virchows Arch 2012;460:3-8.

Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Cancer


Samimi H, Zaki Dizaji M, Ghadami M, Khashayar P, Soleimani M, Larijani B, et al. Essential genes in thyroid cancers: focus on fascin. J Diabetes Metab Disord


Akaishi J, Sugino K, Kitagawa W, Nagahama M, Kameyama K, Shimizu K, et al. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 2011;21:1183-9.

Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13:453-64.

Pinto N, Black M, Patel K, Yoo J, Mymryk JS, Barrett JW, et al. Genomically driven precision medicine to improve outcomes in anaplastic thyroid cancer. J Oncol2014;2014:936285.

Perri F, Pezzullo L, Chiofalo MG, Lastoria S, Di Gennaro F, Scarpati GDV, et al. Targeted therapy: a new hope for thyroid carcinomas. Crit Rev Oncol Hematol 2015;94:55-63.

Denaro N, Nigro CL, Russi EG, Merlano MC. The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer. Onco Targets Ther 2013;9:1231-41.

ClinicalTrial. (Accessed December 2016, 30, at

medchemexpress. (Accessed December 2016, 30, at

selleckckem. (Accessed December 2016, 30, at

Kasaian K, Wiseman SM, Walker BA, Schein JE, Zhao Y, Hirst M, et al. The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy. BMC Cancer 2015;15:984.

Kunstman JW, Juhlin CC, Goh G, Brown TC, Stenman A, Healy JM, et al. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum Mol Genet 2015;24:2318-29.

Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and PI3K/Akt and MAP kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 2008;93:3106-16.

Smith N, Nucera C. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations. J Clin Endocrinol Metab 2014;100:35-42.

Onoda N, Nakamura M, Aomatsu N, Noda S, Kashiwagi S, Kurata K, et al. Significant cytostatic effect of everolimus on a gefitinib-resistant anaplastic thyroid cancer cell line harboring PI3KCA gene mutation. Mol Clin Oncol 2015;3:522-6.

Onoda N, Nakamura M, Aomatsu N, Noda S, Kashiwagi S, Hirakawa K. Establishment, characterization and comparison of seven authentic anaplastic thyroid cancer cell lines retaining clinical features of the original tumors. World J Surg 2014;38:688-95.

Liu D, Hou P, Liu Z, Wu G, Xing M. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 2009;69:7311-9.

Liu D, Xing J, Trink B, Xing M. BRAF mutation‐selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic‐potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer 2010;127:2965-73.

Pilli T, Prasad KV, Jayarama S, Pacini F, Prabhakar BS.

Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer. Thyroid 2009;19:1333-42.

Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008;93:4331-41.

Nagayama Y, Yokoi H, Takeda K, Hasegawa M, Nishihara E, Namba H, et al. Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. The J Clin Endocrinol Metab 2000;85:4081-6.

Meireles AM, Preto A, Rocha AS, Rebocho AP, Máximo V, Pereira-Castro I, et al. Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid 2007;17:707-15.

Zhang L, Zhang Y, Mehta A, Boufraqech M, Davis S, Wang J, et al. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer. Oncotarget 2015;6:9073-85.

Liu D, Xing M. Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-κB pathways. Thyroid 2008;18:853-64.

Saiselet M, Floor S, Tarabichi M, Dom G, Hébrant A,van Staveren WC, et al. Thyroid cancer cell lines: an overview. Front Endocrinol (Lausanne) 2012;3:133.

Haghpanah V, Fallah P, Tavakoli R, Naderi M, Samimi H, Soleimani M, et al. Antisense-miR-21 enhances differentiation/apoptosis and reduces cancer stemness state on anaplastic thyroid cancer. Tumor Biol 2016;37:1299-308.

Guo Z, Hardin H, Lloyd RV. Cancer stem-like cells and thyroid cancer. Endocr Relat Cancer 2014;21:T285-300.

Gao YJ, Li B, Wu XY, Cui J, Han JK. Thyroid tumor- initiating cells: Increasing evidence and opportunities for anticancer therapy (Review). Oncol Rep 2014;31:1035-42.

Fierabracci A. Identifying thyroid stem/progenitor cells:advances and limitations. J Endocrinol 2012;213:1-13.

Shimamura M, Nagayama Y, Matsuse M, Yamashita S, Mitsutake N. Analysis of multiple markers for cancer stem-like cells in human thyroid carcinoma cell lines. Endocr J 2014;61:481-90.

Haghpanah V, Fallah P, Naderi M, Tavakoli R, Soleimani M, Larijani B. Cancer stem-like cell behavior in anaplastic thyroid cancer: A challenging dilemma. Life Sci 2016;146:34-9.

Regad T. Targeting RTK Signaling Pathways in Cancer.Cancers 2015;7:1758-84.

Chiarini F, Evangelisti C, McCubrey JA, Martelli AM.Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci 2015;36:124-35.

Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:103-19.

Saji M, Ringel MD. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol 2010;321:20-8.

Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 2010;20:697-706.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006;46:249-79.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006;46:249-79.

Steelman LS, Chappell WH, Abrams SL, Kempf CR, Long J, Laidler P, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 2011;3:192-22.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.